AI Turns Daily Home OCT Images into Actionable Disease Insights for Retina Specialists
Manassas, Virginia--(Newsfile Corp. - August 26, 2025) - A new study published in Ophthalmology Science validates that artificial intelligence (AI) can accurately track disease activity in patients with wet age-related macular degeneration (AMD) by analyzing up-to daily home OCT images.1 This approach adds a new dimension to patient management by allowing physicians to follow biomarker trajectories over time and assess response to treatment more effectively.The SCANLY Home OCT enables...
2025-08-26 8:00 AM EDT
Pivotal Data Validates Diagnostic Equivalence of SCANLY Home OCT and In-Office OCT in Wet AMD Management
Manassas, Virginia--(Newsfile Corp. - July 9, 2025) - Notal Vision, a digital healthcare provider advancing remote patient monitoring in ophthalmology, announced the publication of pivotal study data in Ophthalmology Science validating the clinical performance and patient usability of the SCANLY Home OCT in the management of neovascular age-related macular degeneration (AMD).¹ The results contributed to the FDA's first-ever clearance of an AI-powered home OCT device for use in...
2025-07-09 8:00 AM EDT
Hadley and Notal Vision Partner to Empower Patients with Vision Loss Through Education and Leading Technology
Winnetka, Illinois--(Newsfile Corp. - June 24, 2025) - Hadley, a leading nonprofit empowering people with vision loss to adapt and thrive, and Notal Vision, a pioneer in AI-driven home diagnostic tools and digital healthcare for retinal diseases, today announced a strategic partnership to bridge the gap between early detection, treatment monitoring, and adaptive living for patients with age-related macular degeneration (AMD). The collaboration will connect users of Notal Vision's ForeseeHome...
2025-06-24 8:00 AM EDT
Home OCT Impacts Physician Decision Making
Manassas, Virginia--(Newsfile Corp. - April 22, 2025) - Digital healthcare provider, Notal Vision, announced that the results of a new study evaluating the impact of home OCT data on disease management decisions for neovascular age-related macular degeneration (nAMD) patients were published in the Journal of VitreoRetinal Diseases. While several studies have shown feasibility of home OCT monitoring with nAMD patients acquiring near daily scans, this is the first-ever study to demonstrate...
2025-04-22 8:00 AM EDT
Notal Vision Announces a Pivotal Study Demonstrating the Efficacy of AI in Enabling Home OCT Monitoring
Manassas, Virginia--(Newsfile Corp. - February 3, 2025) - Digital healthcare provider, Notal Vision, announced that the results of a pivotal study evaluating the performance of an artificial intelligence (AI) algorithm for the estimation of key biomarkers in neovascular AMD (nAMD) using a home-based optical coherence tomography (OCT) system, were recently published in Ophthalmology Science.1 The publication details the study that led to the first-ever US Food and Drug Administration (FDA)...
2025-02-03 8:00 AM EST
AI-powered Home Monitoring Data Presented at Academy 2024
Manassas, Virginia--(Newsfile Corp. - October 30, 2024) - Digital healthcare provider, Notal Vision, announced today that key data on the ForeseeHome AMD Monitoring Program will be shared at Academy 2024, the upcoming annual American Academy of Optometry meeting taking place Wednesday, Nov. 6, through Saturday, Nov. 9, at the Indiana Convention Center in Indianapolis. Two posters on display will show that artificial intelligence (AI)-powered home monitoring makes a meaningful impact in the...
2024-10-30 8:00 AM EDT
Prospective Trial Shows Impact of Home OCT Guided Wet AMD Patient Management
Manassas, Virginia--(Newsfile Corp. - June 25, 2024) - Digital healthcare provider, Notal Vision, announced the results from the first-ever prospective clinical trial using home-based optical coherence tomography (OCT) to manage neovascular age-related macular degeneration (nvAMD) patients in an investigational setting have been published in RETINA©. The publication demonstrated a significant reduction in office visits and treatment frequency, while visual acuity remained stable.The...
2024-06-25 8:00 AM EDT
FDA Grants AI-Powered Notal Vision Home OCT "SCANLY" De Novo Marketing Authorization
Manassas, Virginia--(Newsfile Corp. - May 16, 2024) - Digital healthcare provider, Notal Vision, announced today that the US Food and Drug Administration (FDA) has granted De Novo authorization for its patient self-operated SCANLY® Home OCT device. Designated by the FDA as a Breakthrough Device for patients suffering from wet, or neovascular, age-related macular degeneration (nvAMD), SCANLY Home OCT aims to help improve personalized care for these patients. SCANLY captures spectral-domain...
2024-05-16 9:00 AM EDT